CD8A and neoplasm: We found that replacing the CD8 hinge and transmembrane domain (HTM) and the 4-1BB co-stimulatory domain (CSD) of our recently reported clinical grade FGFR4 targeting CAR with CD28 HTM and CSD resulted in increased cytotoxicity in vitro and improved anti-tumor efficacy in vivo.